335 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Quarry LP

Quarry LP bought a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 335 shares of the company’s stock, valued at approximately $49,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth approximately $27,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $43,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $44,000. Fairfield Financial Advisors LTD bought a new position in Johnson & Johnson during the second quarter worth $46,000. Finally, Grayhawk Investment Strategies Inc. lifted its holdings in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on JNJ shares. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. TD Cowen dropped their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. The Goldman Sachs Group reduced their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

NYSE:JNJ opened at $160.28 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a market cap of $385.74 billion, a PE ratio of 9.99, a PEG ratio of 2.69 and a beta of 0.52. The firm has a 50-day moving average of $162.60 and a 200-day moving average of $154.33.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the company posted $2.80 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.